Principal Investigator: Dr. Ally Olotu
Project leader/ Coordinator: Nikolai Carl Hodel
Project Administrator: Rashid Salim
Funding Partner: University Hospital Basel through Swiss TPH
Start date: April 1, 2023
End date: March 31, 2024
Longitudinal assessment of chronic kidney disease (CKD) prevalence rates and risk factors in a primary care setting in semi rural sub-Saharan Africa
This study which will simply be known as "RenalTWO" is the first longitudinal investigation on chronic kidney disease (CKD) epidemiology in sub-Saharan Africa.
The study will focus on CKD, diabetes and hypertension and will look at the prevalence, incidence, risk signature and diagnostics of each disease.
The study site will be Bagamaoyo District, Tanzania and specifically at the Bgamayo District Hospital (BDH) and at Fukayosi and Yombo dispensaries.
The study is expected to recruit 2,400 participants who fit certain criteria (≥ 18 years of age, of African descent, living in the BDH catchment area and not attending BDH for acute trauma.
The study duration of the RenalTwo project is one year, starting rom April 1, 2023, to March 31, 2024.
Support and funding of the study comes from the Medical Outpatient Clinic at the University Hospital Basel through Swiss TPH.